Clover, GSK collaborate on Coronavirus vaccine candidate S-Trimer
Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate
GlaxoSmithKline (GSK) and Clover Biopharmaceuticals
Clover Biopharmaceuticals | Science | Trimer-Tag™
Clover Biopharmaceuticals | Home
GSK recruits Clover Biopharmaceuticals in latest coronavirus effort - PharmaTimes
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates | Nature Communications
Fierce Pharma Asia—WuXi-BMS plant deal; Clover-GSK COVID-19 vax pact ends; Illumina-Sequoia genomics incubator | Fierce Pharma
Clover nears pivotal trial of GSK-adjuvanted COVID-19 vaccine | Fierce Biotech
Clover Biopharmaceuticals: Phase 1 COVID-19 Vaccine Results - Infectious Disease Advisor
Clover and GSK Announce Research Collaboration to Evaluate Coronavirus (COVID-19) Vaccine Candidate with Pandemic Adjuvant System - Clover Biopharmaceuticals
Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial - The Lancet
Clover | Science | Trimer-Tag™ Oncology
PharmaBoardroom - China's Clover Biopharmaceuticals Partners with GSK on COVID-19 Vaccine
Clover Biopharmaceuticals starts construction of new R&D center in Shanghai
Clover Biopharmaceuticals | Science | Trimer-Tag™
Magnetic and trimer order parameters. a "Clover-leaf" structural domain... | Download Scientific Diagram
Clover Biopharmaceuticals Biomanufacturing Facility, Changxing, China
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
CEPI expands Covid-19 vaccine alliance with Clover Biopharmaceuticals - Pharmaceutical Technology
Drug Discovery News on Twitter: "#Dynavax to provide #TLR9 agonist #adjuvant CpG 1018 to help #Clover #Biopharma evaluate its #COVID19 #vaccine lead #Coronavirus S-trimer subunit vaccine developed using Clover's Trimer-Tag platform https://t.co ...
CEPI announces COVID-19 vaccine development partnership with Clover Biopharmaceuticals' Australian Subsidiary - Clover Biopharmaceuticals
Clover Biopharma nabs $250M-plus for COVID-19 vaccine in expanded CEPI deal | Fierce Biotech
CEPI to provide up to $328m for development of Clover's Covid-19 vaccine
